FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma.

ABSTRACT:

Purpose

The standard treatment of peritoneal pseudomyxoma is based on cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC). The establishment of newer systemic treatments is an unmet clinical need for unresectable or relapsed peritoneal pseudomyxoma. The aim of our study was to assess the activity of chemotherapy with 5-fluorouracil and oxaliplatin (FOLFOX-4 regimen) in terms of response rate in this subset of patients.

Materials and methods

Patients were included in a single-center, observational study and treated with FOLFOX-4 administered every 2 weeks for up to 12 cycles or until progressive disease or unacceptable toxicity.

Results

Twenty consecutive patients were reviewed from July 2011 to September 2013. Only partial responses w

SUBMITTER: Pietrantonio F 

PROVIDER: S-EPMC4122474 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature